BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Early pregnancy factor, Rosiglitazone, rs2230926, FXYD4, T cell differentiation, Lung)
Bookmark Forward

QuickView for copper chaperone activity (biogroup)


Body Atlas

Most Correlated Tissues

  1. Kidney
  2. Spleen
  3. Kidney cortex
  4. Thyroid gland
  5. Vulva
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Menkes kinky-hair syndrome
  2. Injury of eye region
  3. Bacterial septicemia
  4. Renal interstitial fibrosis
  5. Multiple-resistant Staphylococcus aureus infection
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. Linseed Oil
  2. DEC-205 receptor
  3. CGP 60474
  4. temsirolimus
  5. AT 7519
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. GNPTAB
  2. HPGDS
  3. PABPN1
  4. PTGDS
  5. CAT
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

  1. L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
  2. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
  3. L1000 CMAP - Hepatocellular carcinoma Hep G2 cells with shRNA-mediated gene knockdown (1 of 2)
  4. L1000 CMAP - T-cell ALL JURKAT cells treated with small molecule perturbagens
  5. L1000 CMAP - Motor neuron MNEU.E cells treated with small molecule perturbagens
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Involvement of a novel copper chaperone in tyrosinase activity and melanin synthesis in Marinomonas …
  2. Cytosolic superoxide dismutase (SOD1) is critical for tolerating the oxidative stress of zinc defici…
  3. Role of antioxidant-1 in extracellular superoxide dismutase function and expression.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Human Biomarkers for Assessing Copper Deficiency
  2. Establishment of Human Cellular Disease Models for Wilson Disease
  3. Targeting ER Stress in Vascular Dysfunction
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.